Nasdaq:US$13.20 (+0.00) | HKEX:HK$20.25 (-0.45) | AIM:£2.19 (+0.01)
Search Result
Previous Article   |   Next Article
Scientific Publications | 4 Jun 2021

ASCO 2021: An Open-Label Phase 1b/2 Study of Surufatinib in Combination with Tislelizumab  in Patients with Advanced Solid Tumors